Adding colchicine to tocilizumab in hospitalized patients with severe COVID-19 pneumonia: An open-label randomized controlled trial-Reference-Cited by-同舟云学术

Adding colchicine to tocilizumab in hospitalized patients with severe COVID-19 pneumonia: An open-label randomized controlled trial

Published:2022-09-30 Issue:39 Volume:101 Page:e30618
ISSN:1536-5964
Container-title:Medicine
language:en
Short-container-title:

Author:

Rahhal Alaa,Najim Mostafa,Aljundi Amer Hussein,Mahfouz Ahmed,Alyafei Sumaya Mehdar,Awaisu Ahmed,Habib Mhd, Baraa,Obeidat Ibrahim,Faisal Mohanad Mohammed,Alanzi Meshaal Ali,Nair Arun Prabhakaran,Elhassan Areeg,Al-Dushain Abdullah,Abdelmajid Alaaeldin Abdelmajid,Abdelgader Ahmed Elfadil,Moursi Ahmed Mahmoud Ahmed,Alharafsheh Ahmad Eid Nazzal,Kamar Mohd Ragheb Abou,Goravey Wael,Omar Amr Salah,Abukhattab Mohammed,Khatib Mohamad Yahya,Mohamedali Mohamed Gaafar,AlMaslamani Muna A. Rahman,Alemadi Samar

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

General Medicine

Reference24 articles.

1. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China;Huang;Lancet,2020

2. An interactive web-based dashboard to track COVID-19 in real time;Dong;Lancet Infect Dis,2020

3. COVID-19 acute respiratory distress syndrome (ARDS): clinical features and differences from typical pre-COVID-19 ARDS;Gibson;Med J Aust,2020

4. COVID-19: consider cytokine storm syndromes and immunosuppression;Mehta;Lancet,2020

5. Anti-inflammatory therapy for COVID-19 infection: the case for colchicine.;Reyes;Ann Rheum Dis,2020

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Tocilizumab for the treatment of COVID-19;Expert Review of Anti-infective Therapy;2023-06-19

2. Inflammasomes: a rising star on the horizon of COVID-19 pathophysiology;Frontiers in Immunology;2023-05-12

3. SARS-CoV-2-mediated liver injury: pathophysiology and mechanisms of disease;Inflammation Research;2022-12-20